ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1857

Identification Of SOX5 and SOX6 As Potent Regulators Of RANKL Expression Contributing To Bone Erosion In Rheumatoid Arthritis and Experimental Arthritis Model

Wenfeng Tan1, Xiaoke Feng2, Lingxiao Xu3, Ke Gan4, Fang Wang3, Miaojia Zhang5, Hui Wu6 and Betty P. Tsao7, 1Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 2Rheumatology, the First Affiliated Hospital of Nanjing Medical University, China, Nanjing, China, 3Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China, 4Rheumatology Department, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 5Department of Rheumatology, Jiangsu Provincial People's Hospital, Nanjing, China, 6Rheumatology, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 7Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Bone, RANK/RANKL pathway, rheumatoid arthritis (RA) and transcription factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

We previously reported a RANKLpromoter SNP confers an elevated promoter activity after stimulation via binding to a SOX family transcription factor SOX5 and is associated with younger age at onset of rheumatoid arthritis (RA). Here, we examine the expression of SOX family in RA patients and to elucidate their potential role in RA pathogenesis.

Methods:

SOX expression levels in PBMC, plasma, and synovium were tested using RT-PCR, ELISA and immunohistochemistry.  RNA interference and immunoprecipitation were used to determine the role of SOX5 and 6 on cytokine mediated RANKLexpression. Effect of SOX5 and 6 on bone erosion was analyzed using collagen-induced arthritis (CIA) model.

Results:

Among the 9 SOX family genes, expression of SOX5 and SOX6 were robust  in 42 RA PBMC and 20 RA synovium smples.  Compared to 40 osteoarthritis (OA) and 40 healthy controls (HC) samples, increased expression of SOX5 and 6 were observed consistently in PBMC (p<0.05, respectively), plasma (p=0.0002,p=0.0378, respectively) and synovium (p=0.0205,p<0.0001, respectively) from RA patients.  Both SOX5 and 6 could be co-immunoprecipitated with Mab specific to RANKL upon TNFα and IL6 stimulation of rheumatoid fibroblast-like synoviocytes MH7A.   An increase in RANKL expression was observed in MH7A after TNFα and IL6 treatment.  Transfectiom with SOX5 and/or SOX6-shRNA significantly downregulated cytokine-mediated RANKL upregulation in MH7A.  Intra-articular injection of lentivirus expressing shRNA for SOX5 and/or 6 gene silenced RANKL expression,  suppressed arthritic development,  and markedly ameliorated bone erosion inDAB/1mice of a CIA model.

Conclusion:

These findings identify SOX5 and 6 as potential targets for inhibition RANKL expression and preventing bone erosion in RA.


Disclosure:

W. Tan,
None;

X. Feng,
None;

L. Xu,
None;

K. Gan,
None;

F. Wang,
None;

M. Zhang,
None;

H. Wu,
None;

B. P. Tsao,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-sox5-and-sox6-as-potent-regulators-of-rankl-expression-contributing-to-bone-erosion-in-rheumatoid-arthritis-and-experimental-arthritis-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology